p Values | ||||
CFH genotype | TT | TC | CC | |
Frequency (%) | 26 (25%) | 53 (50.9%) | 25 (24.1%) | |
Mean baseline BCVA letter score (SD) | 53.5 (18.0) | 51.3 (14.1) | 49.8 (16.9) | |
Mean BCVA letter score change after 6 months (SD) | +1.6 (13.1) | +5.9 (14.6) | +7.2 (11.7) | 0.18*, 0.71* |
Number with >5 BCVA letter score gain after 6 months (%) | 9 (34.6%) | 30 (56.6%) | 14 (56%) | 0.04*, 0.4* |
Mean number of injections in 6 months (SD) | 4.1 (0.8) | 4.1 (0.9) | 3.7 (1.1) | |
HTRA1 genotype | GG | GA | AA | |
Frequency (%) | 27 (26%) | 55 (52.9%) | 22 (21.1%) | |
Mean baseline BCVA letter score (SD) | 51.0 (14.4) | 50.7 (15.6) | 54.1 (18.0) | |
Mean BCVA letter score change after 6 months (SD) | +2.2 (14.4) | +7.5 (13.2) | +2.9 (13.4) | 0.03*, 0.55* |
Number with >5 BCVA letter score gain after 6 months (%) | 13 (48.1%) | 30 (54.5%) | 10 (45.5%) | 0.16*, 0.59* |
Mean number of injections in 6 months (SD) | 4.0 (0.9) | 4.0 (1.0) | 4.2 (1.0) | |
VEGF genotype | TT | TC | CC | |
Frequency (%) | 25 (24.1%) | 52 (50%) | 27 (25.9%) | |
Mean baseline BCVA letter score (SD) | 51.3 (15.7) | 52.6 (14.2) | 49.5 (18.6) | |
Mean BCVA letter score change after 6 months (SD) | +1.3 (12.7) | +5.8 (14.8) | +7.4 (11.8) | 0.11*, 0.11* |
Number with >5 BCVA letter score gain after 6 months (%) | 10 (40%) | 29 (55.8%) | 14 (51.9%) | 0.08*, 0.38* |
Mean number of injections in 6 months (SD) | 4.2 (1.0) | 3.9 (0.9) | 4.1 (1.0) |
↵* Compared with the lower risk CFH TT, HTRA1 GG and VEGF TT genotypes in multivariate analysis.
BCVA, best corrected visual acuity; CFH, complement factor H; HTRA1, high-temperature requirement factor A-1; VEGF, vascular endothelial growth factor.